The healthcare market showcased a lively after-hours trading session on Monday, witnessing both upward and downward shifts across various companies. This summary highlights the key movements, illustrating the dynamic nature of stock valuations influenced by recent corporate news and investor sentiment.
Detailed After-Market Healthcare Stock Performance Analysis
On Monday, November 24, 2025, following the close of regular trading, a dozen healthcare-related stocks demonstrated considerable movement, captivating investors. These shifts provide a snapshot of the sector's health and potential future trends.
Among the top performers, Addex Therapeutics (ADXN) experienced a robust increase, climbing 12.1% to settle at $8.18, pushing its market valuation to $7.2 million. Similarly, Cassava Sciences (SAVA) saw its shares rise by 8.96% to $3.16, contributing to its substantial market capitalization of $138.6 million. Purple Biotech (PPBT) also posted a solid gain, with its stock price advancing 8.26% to $0.89, placing its market cap at $6.9 million. Further positive movements included Biodexa Pharmaceuticals (BDRX), which rose 7.63% to $4.65, achieving a market cap of $2.7 million. iSpecimen (ISPC)'s stock moved up by 3.75% to $0.48, resulting in a market cap of $4.1 million. Lastly, NovaBridge Biosciences (NBP) shares increased by 3.47% to $4.15, boasting a significant market capitalization of $487.5 million.
However, the after-market session also brought declines for several companies. Pasithea Therapeutics (KTTA) faced a considerable drop, with its stock falling 12.9% to $0.37, bringing its market cap to $2.1 million. Aditxt (ADTX) shares decreased by 6.45% to $3.34, with a market value of $1.3 million, reportedly influenced by its Q3 earnings report released four days prior. Tenax Therapeutics (TENX) saw a 5.34% reduction in its stock price, landing at $8.52 and holding a market cap of $50.8 million. Mobile-health Network (MNDR) experienced a 5.14% decline to $2.77, with its market cap noted at $11.3 million. Can Fite Biofarma (CANF) stock also dipped by 3.01% to $0.32, leading to a market cap of $4.9 million. Finally, Profusa (PFSA)'s stock fell 2.94% to $0.15, with a market cap of $5.7 million, following its Q3 earnings announcement three days earlier.
The dynamic movements observed in Monday's after-market healthcare trading underscore the sector's sensitivity to news, earnings, and investor sentiment. For market participants, these shifts highlight the importance of staying informed and agile. The varied performance across these 12 companies suggests a market that, while overall robust, rewards certain developments and penalizes others, offering both opportunities and risks for discerning investors.